A Study of Eszopiclone in Subjects With Insomnia Related to Major Depressive Disorder

Depression Response to Eszopiclone in Adults With Major Depressive Disorder (DREAMDD): A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 8-Week, Safety & Efficacy Study of Eszopiclone 3 mg Compared to Placebo in Subjects With Insomnia Related to MDD Acronym: DREAMDD

The purpose of this study is to evaluate subjective sleep efficacy in subjects with insomnia related to major depressive disorder.

Study Overview

• Status: Completed
• Conditions: Insomnia; Depressive Disorder, Major
• Intervention / Treatment: Other: Placebo; Drug: Eszopiclone

Detailed Description

This study is a double-blind, randomized, placebo-controlled, parallel group study. The study consists of two groups of subjects with major depression treated for ten weeks with a common antidepressant regimen, 20-40 mg of fluoxetine hydrochloride per day; and randomized to receive (in addition) either eszopiclone 3 mg or placebo for eight weeks. This study was previously posted by Sepracor Inc. In October 2009, Sepracor Inc. was acquired by Dainippon Sumitomo Pharma., and in October 2010, Sepracor Inc's name was changed to Sunovion Pharmaceuticals Inc.

• Study Type: Interventional
• Enrollment (Actual): 545
• Phase: Phase 3

Contacts and Locations

Study Locations

• United States
  • Alabama
    • Birmingham, Alabama, United States
  • Arizona
    • Peoria, Arizona, United States
    • Tucson, Arizona, United States
  • Arkansas
    • Fayetteville, Arkansas, United States
  • California
    • Garden Grove, California, United States
    • Irvine, California, United States
    • Northridge, California, United States
    • Riverside, California, United States
    • San Diego, California, United States
  • Colorado
    • Wheat Ridge, Colorado, United States
  • Connecticut
    • New Britian, Connecticut, United States
  • Florida
    • Jacksonville, Florida, United States
    • Miami, Florida, United States
    • Miami Beach, Florida, United States
    • North Miami, Florida, United States
    • St. Petersburg, Florida, United States
  • Georgia
    • Atlanta, Georgia, United States
    • Augusta, Georgia, United States
    • Decatur, Georgia, United States
    • Smyrna, Georgia, United States
  • Idaho
    • Boise, Idaho, United States
  • Kansas
    • Overland Park, Kansas, United States
  • Maryland
    • Rockville, Maryland, United States
  • Massachusetts
    • Boston, Massachusetts, United States
    • Braintree, Massachusetts, United States
    • Brighton, Massachusetts, United States
    • Brockton, Massachusetts, United States
    • Cambridge, Massachusetts, United States
    • Watertown, Massachusetts, United States
  • Michigan
    • Farmington Hills, Michigan, United States
  • Missouri
    • St Louis, Missouri, United States
  • Nebraska
    • Omaha, Nebraska, United States
  • New Jersey
    • Clementon, New Jersey, United States
    • Morestown, New Jersey, United States
  • New York
    • Bronx, New York, United States
    • Lawerence, New York, United States
    • New York, New York, United States
  • North Carolina
    • Durham, North Carolina, United States
    • Winston-Salem, North Carolina, United States
  • North Dakota
    • Bismarck, North Dakota, United States
  • Ohio
    • Beachwood, Ohio, United States
    • Cincinatti, Ohio, United States
    • Dayton, Ohio, United States
  • Oklahoma
    • Oklahoma City, Oklahoma, United States
  • Oregon
    • Eugene, Oregon, United States
    • Portland, Oregon, United States
    • Salem, Oregon, United States
    • Springfield, Oregon, United States
  • Pennsylvania
    • Conshohocken, Pennsylvania, United States
    • Emmaus, Pennsylvania, United States
    • Philadelphia, Pennsylvania, United States
    • Scotland, Pennsylvania, United States
  • South Carolina
    • Anderson, South Carolina, United States
  • Tennessee
    • Madison, Tennessee, United States
    • Memphis, Tennessee, United States
    • Selmer, Tennessee, United States
  • Texas
    • Austin, Texas, United States
    • San Antonio, Texas, United States
    • Wichita Falls, Texas, United States
  • Utah
    • Salt Lake City, Utah, United States
  • Virginia
    • Richmond, Virginia, United States
  • Washington
    • Lakewood, Washington, United States
    • Seatle, Washington, United States
    • Spokane, Washington, United States
  • Wisconsin
    • Madison, Wisconsin, United States

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 21 years to 64 years (Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Subject must understand the purpose of the study and be willing to adhere to the study schedule and procedures described in this protocol.
• Subject must be 21 to 64 years of age (inclusive) on the day of signing consent.
• Subject must meet criteria for a primary and principal diagnosis of Major Depressive Disorder.
• Subject's current depressive episode is at least 2 weeks but not longer than 6 months in duration.
• Subject must meet criteria for insomnia related to MDD and the symptoms of insomnia must not pre-date the symptoms of MDD by more than 10 weeks.
• Subject must report a sleep onset time of > 30 minutes, and wake time after sleep onset of > 45 minutes, and < 6.5 hours of total sleep time at least three times a week over the previous month.
• Subject must take the Hamilton-D-17 scale and have a protocol pre-specified minimum score.
• Subject must have no known clinically significant abnormal laboratory, ECG, or physical examination findings at screening.
• Subject must meet one of the following conditions:
• Subject is not taking antidepressant medications at the time of study start.
• Subject is taking a sub-therapeutic dose of antidepressant or other disallowed psychotropic medication and with the approval of the investigator agrees to taper off of this medication, prior to completion of screening assessments at study start.

Exclusion Criteria:

• Female subject is pregnant, lactating or within 6 months post partum.
• Subject has known sensitivity to any selective SSRI, zopiclone, or eszopiclone.
• Subject has history of major depressive disorder that was refractory to treatment with SSRIs.
• Subject has a current primary psychiatric diagnosis of any of the following disorders: dementia, delirium, schizophrenia, psychosis, other psychotic disorders, dysthymic disorder; bipolar disorders; cyclothymic disorder, other mood disorders, nocturnal panic disorder, primary anxiety disorders, primary panic disorders or any other psychiatric disorder that would compromise the investigator's ability to evaluate the safety and efficacy of the study medication.
• Note: Subjects with Sexual and Gender Identity Disorders or other non-psychotic disorders will be considered on a case-by-case basis. Subjects with MDD and a secondary diagnosis of generalized anxiety disorder, panic disorders other than nocturnal panic disorder or seasonal affective disorder will be allowed.
• Subject has any of the following Personality Disorders diagnoses: schizotypal, schizoid, borderline personality disorder; mental retardation or any other personality disorder that would compromise the investigator's ability to evaluate the safety and efficacy of the study medication.
• Subject has difficulties in sleep initiation or maintenance associated with known medical diagnosis [e.g. sleep apnea, restless leg syndrome (RLS), or periodic leg movement syndrome (PLMS)], or has any condition that has or may affect sleep [(e.g., chronic pain, benign prostatic hypertrophy (BPH)].
• Subject has any clinically significant unstable medical or neurologic abnormality, unstable chronic disease, or a history of a clinically significant abnormality of the cardiovascular, respiratory, hepatic, or renal systems.
• Subject has a disorder or history of a condition (e.g., malabsorption, gastrointestinal surgery) that may interfere with drug absorption, distribution, metabolism, or excretion.
• Subject has a history of malignancy within 5 years, or current malignancy, except for non-melanoma skin cancer.
• Subject has a history of drug or alcohol abuse or dependence in the past 6 months or positive urine drug and alcohol test at screening.
• Subject is participating in, has participated in, or plans to participate in any investigational drug study within 30 days prior to screening until the end of this study.
• Subject has history of circadian rhythm disorder, or travels across >3 time zones on a regular basis.
• Subject is known to be seropositive for Human Immunodeficiency Virus (HIV).
• Subject has used any drugs known or suspected to affect hepatic or renal clearance capacity within a period of 30 days prior to screening.
• Subject is unwilling to refrain from drinking alcoholic beverages during study participation.
• Subject is a rotating or third/night shift worker.
• Subject is a staff member or relative of a staff member.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Double

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Placebo Comparator: B; Placebo tablet	Other: Placebo; Placebo tablet
Experimental: A; Eszopiclone 3 mg QD	Drug: Eszopiclone; Eszopiclone 3 mg QD; Other Names: Lunesta, (S)-Zopliclone

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Mean subjective wake time after sleep onset (WASO)	1 week

Secondary Outcome Measures

Outcome Measure	Time Frame
Time to onset of 30% antidepressant response using the HAM-D-6 (Bech)
Mean WASO	Weeks 2, 3, 4, 6 and 8
Mean subjective total sleep time (TST)	Weeks 1, 2, 3, 4, 6, and 8
Mean subjective sleep latency (SL)	Weeks 1, 2, 3, 4, 6, and 8
Mean number of awakenings	Weeks 1, 2, 3, 4, 6, and 8
Quality and depth of sleep	Weeks 1, 2, 3, 4, 6 and 8
Daytime alertness	Weeks 1, 2, 3, 4, 6 and 8
Ability to concentrate	Weeks 1, 2, 3, 4, 6 and 8
Physical well-being	Weeks 1, 2, 3, 4, 6 and 8
Ability to function	Weeks 1, 2, 3, 4, 6, and 8
average rebound and withdrawal effects will be analyzed for each of the subjective sleep endpoints	Weeks 1, 2, 3, 4, 6, and 8
Time to onset of 50% antidepressant response using the HAM-D-6 (Bech)	Weeks 1, 2, 3, 4, 6, and 8
Time to onset of 50% and 30% antidepressant responses using the HAM-D-6 (Maier)	Weeks 1, 2, 3, 4, 6, and 8
Change in the HAM-D-6 (Bech) and HAM-D-6 (Maier) from baseline to each visit	Weeks 1, 2, 3, 4, 6, and 8
Change in the HAM-D-17 from baseline	Weeks 4 and 8
Symptom Questionnaire (SQ) Score (Depression Subscale)	Weeks 1, 2, 3, 4, 6, and 8
Daily Telephone Assessment (DTA) Score	Weeks 1, 2, 3, 4, 6, and 8
Change in HAM-D-6 (Bech), HAM-D-6 (Maier), HAM-D-17, SQ, and DTA during the wash-out phase until end of study	Weeks 8 and 10
SF-36 Score	Weeks 4, 8, and 10
Work Limitations Questionnaire (WLQ) Score	Weeks 2, 4, 8, and 10
Epworth Sleepiness Scale (ESS)	Weeks 1, 2, 3, 4, 6, 8, and 10
Insomnia Severity Index (ISI) score	Weeks 2, 4, 8, and 10
Clinical Global Impression	Weeks 1, 2, 3, 4, 6, 8, and 10
Safety will be assessed by physical examinations, a standard 12-lead ECG, vital signs, clinical laboratory assessments and AE reporting	Weeks 1 through 10

Collaborators and Investigators

• Sponsor: Sunovion

Publications and helpful links

General Publications

• Fava M, Schaefer K, Huang H, Wilson A, Iosifescu DV, Mischoulon D, Wessel TC. A post hoc analysis of the effect of nightly administration of eszopiclone and a selective serotonin reuptake inhibitor in patients with insomnia and anxious depression. J Clin Psychiatry. 2011 Apr;72(4):473-9. doi: 10.4088/JCP.09m05131gry. Epub 2010 Nov 2.
• Snedecor SJ, Botteman MF, Schaefer K, Sarocco P, Barry N, Pickard AS. Economic outcomes of eszopiclone treatment in insomnia and comorbid major depressive disorder. J Ment Health Policy Econ. 2010 Mar;13(1):27-35.

Study record dates

Study Major Dates

• Study Start: January 1, 2004
• Primary Completion (Actual): October 1, 2004
• Study Completion (Actual): October 1, 2004

Study Registration Dates

• First Submitted: August 23, 2006
• First Submitted That Met QC Criteria: August 23, 2006
• First Posted (Estimate): August 24, 2006

Study Record Updates

• Last Update Posted (Estimate): February 22, 2012
• Last Update Submitted That Met QC Criteria: February 21, 2012
• Last Verified: February 1, 2012

More Information

Terms related to this study

• Keywords: Insomnia related to major depressive disorder.
• Additional Relevant MeSH Terms: Behavioral Symptoms; Mental Disorders; Pathologic Processes; Nervous System Diseases; Mood Disorders; Sleep Disorders, Intrinsic; Dyssomnias; Sleep Wake Disorders; Depression; Depressive Disorder; Disease; Sleep Initiation and Maintenance Disorders; Depressive Disorder, Major; Physiological Effects of Drugs; Central Nervous System Depressants; Hypnotics and Sedatives; Eszopiclone
• Other Study ID Numbers: 190-052